NVS vs OMER: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NVS is the larger of the two ($307.88B market cap): the incumbent the market prices for continued execution (16.58x forward earnings, beta 0.45). OMER is the smaller challenger ($1.25B), cheaper on forward earnings (14.00x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

NVS vs OMER: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricNVSOMERWhat it tells you
Market cap$307.88B$1.25BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E16.5814.00Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E31.1114.11Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.452.99Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range84% of range73% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: OMER is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how NVS and OMER affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVS and OMER share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVS and OMER exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Novartis AG (NVS) do?

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is at about the same level with net income near $12.8 billion.

Full NVS guide

What does Omeros (OMER) do?

Omeros Corporation develops drugs that target the complement system, the part of innate immunity that turns destructive in certain rare diseases. Its lead product, YARTEMLEA (narsoplimab-wuug), is a MASP-2 antibody approved by the FDA in December 2025 for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children two and older, a condition with high mortality and, until that approval, no approved treatment. Omeros also earns a royalty tail on OMIDRIA, the ophthalmic surgical drug it sold to Rayner in 2021, and in December 2025 it closed a deal handing global rights to its MASP-3 inhibitor zaltenibart (OMS906) to Novo Nordisk for $240 million in cash up front and up to $2.1 billion in total potential payments plus royalties. What remains in house is earlier stage: OMS1029, a long-acting MASP-2 antibody designed for quarterly dosing, and OMS527, a PDE7 inhibitor funded by NIDA for cocaine use disorder.

Full OMER guide

NVS vs OMER: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.
  • OMER drivers: The YARTEMLEA launch curve; A repaired balance sheet, not a raised one.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. For OMER, concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year.

NVS or OMER: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVS if you believe its drivers more; OMER if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVS and OMER guides.

NVS vs OMER: the full fundamentals

NVS. At about $151, NVS trades near 23 times trailing earnings but only about 15 times forward estimates, a gap that reflects reported profit depressed by the Entresto cliff and an expected rebound to about $9.80 of EPS in 2027. The analyst mean target of roughly $155 sits close to the current price, so the October 27 third-quarter report and how fast the growth brands keep absorbing the generic erosion matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.

OMER. Screens that show Omeros at roughly 30 times sales are reading a trailing window that mostly predates the product: YARTEMLEA only began selling in January 2026. Against the second-quarter net revenue run rate of about $114 million annualized, the roughly $1.16 billion market value is about ten times sales, and closer to nine times the 2026 consensus of about $128 million, an ordinary multiple for a rare-disease launch and a demanding one if the ramp stalls. The trailing P/E near 13 is not a clean signal either, because trailing net income of about $117 million includes the Novo Nordisk transaction rather than recurring operations.

Headline figures (approximate, October 2026): NVS shows revenue (ttm) ~$56.7B; Q2 2026 revenue ~$14.95B, up ~1% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~35% operating, ~22.5% net, net income (ttm) ~$12.8B; OMER shows net product revenue (q2 2026) ~$28.5M (~$32.2M gross), up from ~$9.9M in Q1, net product revenue (h1 2026) ~$38.4M, versus $0 a year earlier, net income (q2 2026) ~$13.2M; EPS ~$0.10 vs ~-$0.33 estimate (Yahoo basis), consensus revenue (fy2026 / fy2027) ~$128M / ~$221M.

The bottom line: NVS vs OMER

NVS and OMER are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVS and OMER exposure against your real portfolio. It is not an investment adviser.

Wondering how NVS or OMER fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Novartis AG

Ask Walnut's AI anything about NVS and see how it fits what you own.

FAQ

What is the difference between NVS and OMER?

+

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Omeros Corporation develops drugs that target the complement system, the part of innate immunity that turns destructive in certain rare diseases. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is NVS or OMER the better stock?

+

Neither is universally better. NVS is the larger incumbent; OMER is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, NVS or OMER?

+

On forward P/E (as of November 2026), NVS trades at 16.58x and OMER at 14.00x, so OMER is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both NVS and OMER?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of NVS vs OMER?

+

NVS: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Analysts expect 2026 EPS to slip about 2% before rebounding in 2027, and reported earnings growth was about -17% year over year in the latest quarter. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off. Large acquisitions such as Avidity add integration and financing risk and raised debt, which stood at about $49 billion against about $7.6 billion of cash in mid-2026. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock. OMER: Concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year. A launch that looks steep for two quarters can flatten quickly once prevalent patients are treated, and rare-disease reimbursement can widen gross-to-net deductions over time. The CHMP negative opinion from June 2026 was upheld on re-examination on October 16, 2026, so Europe is off the table for now and US sales have to carry the story alone. Several plaintiffs' firms announced investigations after the resulting share-price drop, and while no filed class action complaint was found, an investigation can turn into one. The company also still carries convertible notes and a shareholders' deficit, so a stumble in the launch would put financing back on the table for a business that has raised money on unfavorable terms before. Insiders sold shares in late August 2026 according to SEC filings, and the stock's 52-week range of roughly $6 to $21 shows how violently sentiment can swing.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NVS or OMER; figures are approximate and dated (as of November 2026). Verify current data before investing.